Tuesday, February 19, 2013

Chugai Files Lawsuit against Iwaki Seiyaku, Takat Seiyaku, Pola Pharma and DKSH Japan Co limited

Chugai Pharmaceutical Co., Ltd. announced today that it has filed a lawsuit to the Tokyo District Court as of February 19, and has also filed a petition for provisional disposition order, demanding the
suspension of patent infringement related to Oxarol® Ointment 25 μg/g, a treatment for keratosis including psoriasis vulgaris against Iwaki Seiyaku Co., Ltd., Takata Seiyaku Co., Ltd., and Pola Pharma Inc., the distributors of the generic drugs of Oxarol® Ointment, as well as DKSH Japan Co., Ltd., the importer of the drug substance of said generic drugs, citing such parties’ infringement of the manufacturing process patent owned by Chugai as the ground.

Oxarol® Ointment is an agent for the treatment of keratosis, using active vitamin D3 derivative maxacalcitol as an active ingredient, which Chugai has discovered. Oxarol® Ointment is indicated for the treatment of four diseases, namely, psoriasis vulgaris, ichthyosis, palmoplantar keratosis, and palmoplantar pustulosis.




Enter your email address:


Delivered by FeedBurner